Literature DB >> 6644792

Serum-induced enhancement of peripheral blood mononuclear cell-mediated cytotoxicity towards human target cells in systemic sclerosis.

C A Penning, J K Wright, J C Ashby, J Cunningham, N R Rowell, P Hughes.   

Abstract

Sera from 7 of 37 patients with systemic sclerosis (SS) were found to markedly enhance cytotoxicity in several established human target cell lines when co-cultured with normal human peripheral blood mononuclear cells (PBM). Fractionation studies indicated that the cytotoxicity-inducing activity resided in the IgG-containing fractions of serum and that the effector cells were Fc-receptor positive. By contrast, sera from 27 normal controls produced little or no cytotoxicity when co-cultured with the same target cell lines and normal PBM. Any slight enhancement of cytotoxicity that occurred with a single target cell line was, on fractionation, either labile or associated with albumin containing fractions. These findings raise the possibility that antibody-dependent cellular cytotoxicity (ADCC) could provide a pathogenetic mechanism in some patients with SS.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6644792

Source DB:  PubMed          Journal:  J Clin Lab Immunol        ISSN: 0141-2760


  3 in total

1.  Antibody-dependent cellular cytotoxicity of vascular endothelium: characterization and pathogenic associations in systemic sclerosis.

Authors:  C M Holt; N Lindsey; J Moult; R G Malia; M Greaves; A Hume; N R Rowell; P Hughes
Journal:  Clin Exp Immunol       Date:  1989-12       Impact factor: 4.330

2.  Pretreatment with lipoteichoic acid sensitizes target cells to antibody-dependent cellular cytotoxicity in the presence of anti-lipoteichoic acid antibodies.

Authors:  D E Lopatin; R E Kessler
Journal:  Infect Immun       Date:  1985-06       Impact factor: 3.441

Review 3.  Pathogenic mechanisms of anti-endothelial cell antibodies (AECA): their prevalence and clinical relevance.

Authors:  Cristiano Alessandri; Michele Bombardieri; Guido Valesini
Journal:  Adv Clin Chem       Date:  2006       Impact factor: 5.394

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.